Adaptimmune Therapeutics (ADAP) Tops Q3 EPS by 14c

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q3 EPS of ($0.03), $0.14 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $14.41 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Accenture downgraded by TD Cowen on AI concerns
• Credo Technology pops 3.5% as Evercore initiates with monster $325 price target